يعرض 1 - 6 نتائج من 6 نتيجة بحث عن '"Harald Ballo"', وقت الاستعلام: 0.86s تنقيح النتائج
  1. 1
    Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study

    المؤلفون: Heinz Dürk, Georg Maschmeyer, Harald Ballo, Manfred Welslau, Eckhart Weidmann, Christina Balser, Ulrich Kaiser, Christoph Losem, Alexander Burchardt, Wolfram Brugger, Gerhard Heil, Frank Kauff, Ulrich von Gruenhagen, Wolfgang Blau, Martina Stauch, Andrea Heider, Mathias J. Rummel, Arnold Ganser, Juergen Barth

    المصدر: Journal of Clinical Oncology. 35:7501-7501

    مصطلحات موضوعية: Bendamustine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, CHOP, medicine.disease, Surgery, First line treatment, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, Internal medicine, medicine, Clinical endpoint, Rituximab, Mantle cell lymphoma, In patient, Indolent lymphomas, business, 030215 immunology, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e9bc7c478904cee9c3e2184351e950faTest
    https://doi.org/10.1200/jco.2017.35.15_suppl.7501Test


    أضف إلى المفضلة
  2. 2
    Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

    المؤلفون: Mathias J, Rummel, Norbert, Niederle, Georg, Maschmeyer, G Andre, Banat, Ulrich, von Grünhagen, Christoph, Losem, Dorothea, Kofahl-Krause, Gerhard, Heil, Manfred, Welslau, Christina, Balser, Ulrich, Kaiser, Eckhart, Weidmann, Heinz, Dürk, Harald, Ballo, Martina, Stauch, Fritz, Roller, Juergen, Barth, Dieter, Hoelzer, Axel, Hinke, Wolfram, Brugger, J, Zimber

    المصدر: Lancet (London, England). 381(9873)

    مصطلحات موضوعية: Bendamustine, Adult, medicine.medical_specialty, Vincristine, Lymphoma, Mantle-Cell, CHOP, Gastroenterology, Disease-Free Survival, Antibodies, Monoclonal, Murine-Derived, immune system diseases, Prednisone, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Indolent Non-Hodgkin Lymphoma, Bendamustine Hydrochloride, Humans, Prospective Studies, Infusions, Intravenous, Cyclophosphamide, Aged, Performance status, business.industry, General Medicine, Middle Aged, medicine.disease, Surgery, Treatment Outcome, Doxorubicin, Nitrogen Mustard Compounds, Rituximab, Mantle cell lymphoma, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42621a9d0dd78b3c56d7d0a2134af82aTest
    https://pubmed.ncbi.nlm.nih.gov/24075045Test


    أضف إلى المفضلة
  3. 3
    Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response

    المؤلفون: Norbert Niederle, Heinz A. Duerk, Martina Stauch, Christina Balser, Axel Hinke, Chrisoph Losem, G.-Andre Banat, Mathias J. Rummel, Manfred Welslau, Ulrich von Grünhagen, Harald Ballo, Wolfram Brugger, Eckhart Weidmann, Juergen Barth, Dorothea Kofahl-Krause, Fritz Roller, Gerhard Heil, Alexander Burchardt, Georg Maschmeyer, Ulrich Kaiser

    المصدر: Blood. 120:2724-2724

    مصطلحات موضوعية: Bendamustine, medicine.medical_specialty, business.industry, Immunology, Phases of clinical research, Cell Biology, Hematology, CHOP, medicine.disease, Biochemistry, Gastroenterology, Surgery, Tolerability, Partial response, Internal medicine, medicine, Mantle cell lymphoma, Rituximab, business, Complete response, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::0ccef860adc174782e4064a32c14781aTest
    https://doi.org/10.1182/blood.v120.21.2724.2724Test


    أضف إلى المفضلة
  4. 4
    Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study

    المؤلفون: Dorothea Kofahl-Krause, Gerhard Heil, Manfred Welslau, Ulrich von Gruenhagen, Heinz A. Duerk, Harald Ballo, Ulrich Kaiser, A. Banat, Martina Stauch, Eckhart Weidmann, Christina Balser, Christoph Losem, Mathias J. Rummel, Axel Hinke, Wolfram Brugger, Juergen Barth, Georg Maschmeyer, Norbert Niederle

    المصدر: Journal of Clinical Oncology. 30:3-3

    مصطلحات موضوعية: Bendamustine, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Patient characteristics, CHOP, Surgery, Indolent lymphoma, First line treatment, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, Clinical endpoint, Rituximab, In patient, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::b6ccac37d5407dea6e3898d72d92635dTest
    https://doi.org/10.1200/jco.2012.30.15_suppl.3Test


    أضف إلى المفضلة
  5. 5
    Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany)

    المؤلفون: Gerhard Heil, Dieter Hoelzer, Christina Balser, Ulrich Kaiser, Georg Maschmeyer, Harald Ballo, Dorothea Kofahl-Krause, Eckhart Weidmann, Mathias J. Rummel, Manfred Welslau, Christoph Losem, Heinz A. Duerk, Wolfram Brugger, Norbert Niederle, Juergen Barth, Axel Hinke, Fritz Roller, Ulrich von Gruenhagen, A. Banat

    المصدر: Blood. 114:405-405

    مصطلحات موضوعية: Bendamustine, medicine.medical_specialty, business.industry, Immunology, Cell Biology, Hematology, Neutropenia, CHOP, medicine.disease, Biochemistry, Gastroenterology, Surgery, Leukocytopenia, Tolerability, Internal medicine, medicine, Mantle cell lymphoma, Rituximab, Progression-free survival, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::903b6254b6f09407a33f025dabd6af73Test
    https://doi.org/10.1182/blood.v114.22.405.405Test


    أضف إلى المفضلة
  6. 6
    Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany)

    المؤلفون: Christina Balser, U. von Gruenhagen, Wolfram Brugger, K. Schalk, Heinz A. Duerk, Manfred Welslau, Harald Ballo, Eckhart Weidmann, F. Rothmann, Gerhard Heil, Christoph Losem, Mathias J. Rummel, Ulrich Kaiser, Dorothea Kofahl-Krause, Norbert Niederle, A. Banat, Martina Stauch, W. U. Knauf, Axel Matzdorff, Dieter Hoelzer

    المصدر: Blood. 110:385-385

    مصطلحات موضوعية: Bendamustine, medicine.medical_specialty, business.industry, Immunology, Cell Biology, Hematology, CHOP, medicine.disease, Interim analysis, Biochemistry, Gastroenterology, Surgery, Regimen, Tolerability, Leukocytopenia, hemic and lymphatic diseases, Internal medicine, medicine, Mantle cell lymphoma, Rituximab, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::c07640eb85deaeceb14f7f297e3e78c1Test
    https://doi.org/10.1182/blood.v110.11.385.385Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث